Severe gastroenteritis in both developed and less developed countries is caused by rotaviruses and currently there is only one licensed vaccine available. Disease aspect of rotavirus results from rapid replication of the virus in i ntestinal cells, outstripping the ability of the intestine to replace damaged cells. The virus is a 70 nm non-enveloped virus containing 11 segments of double stranded RNA genome. To date three structural proteins (VP3, VP4 and VP7) and two non-structural proteins (NSP2 and NSP4) have been shown to be associated with pathogenicity and one nonstructural protein, NSP1 was shown to be associated with host range . Rotaviruses have the ability to establish persistent infections in certain cells in culture, though they are cytocidal in others. However, the mechanism by which the virus establish persistence is not known. Progress: 1) Lab was set-up to perform rotavirus potency testing; Rotavirus plaque-assay for potency testing was developed. Several vaccine lots were released based on in-house potency testing and by review of submitted lot release protocols.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BK002013-02
Application #
6101169
Study Section
Special Emphasis Panel (LPRV)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost